- Research article
- Open Access
Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice
© Dickey et al; licensee BioMed Central Ltd. 2005
- Received: 08 October 2004
- Accepted: 02 February 2005
- Published: 02 February 2005
The pathology of Alzheimer's disease (AD) is comprised of extracellular amyloid plaques, intracellular tau tangles, dystrophic neurites and neurodegeneration. The mechanisms by which these various pathological features arise are under intense investigation. Here, expanding upon pilot gene expression studies, we have further analyzed the relationship between Na+/K+ ATPase and amyloid using APP+PS1 transgenic mice, a model that develops amyloid plaques and memory deficits in the absence of tangle formation and neuronal or synaptic loss.
We report that in addition to decreased mRNA expression, there was decreased overall Na+/K+ ATPase enzyme activity in the amyloid-containing hippocampi of the APP+PS1 mice (although not in the amyloid-free cerebellum). In addition, dual immunolabeling revealed an absence of Na+/K+ ATPase staining in a zone surrounding congophilic plaques that was occupied by dystrophic neurites. We also demonstrate that cerebral Na+/K+ ATPase activity can be directly inhibited by high concentrations of soluble Aβ.
The data suggest that the reductions in Na+/K+ ATPase activity in Alzheimer tissue may not be purely secondary to neuronal loss, but may results from direct effects of amyloid on this enzyme. This disruption of ion homeostasis and osmotic balance may interfere with normal electrotonic properties of dendrites, blocking intraneuronal signal processing, and contribute to neuritic dystrophia. These results suggest that therapies aimed at enhancing Na+/K+ ATPase activity in AD may improve symptoms and/or delay disease progression.
- ATPase Activity
- Amyloid Plaque
- Dystrophic Neurites
- Anterograde Amnesia
Alzheimer's disease (AD) has several well-characterized post-mortem pathological markers that include both gliosis and dystrophic neurites surrounding extracellular amyloid plaques. In addition, intracellular tangles of hyper-phosphorylated tau and massive neurodegeneration are seen later in the disease process. Mutated forms of both amyloid precursor protein (APP) and presenilin 1 (PS1) lead to an increased rate of amyloid deposition and therefore an earlier onset of the dementia associated with AD . Doubly transgenic mice expressing these human mutants of the APP  and PS1  genes (APP+PS1 mice;  exhibit a large amount of amyloid deposition and gliosis without the formation of tangles or neuron loss, and yet they still develop anterograde amnesia as they age, similar to what is seen in the early stages of AD . Memory deficits without the loss of neurons indicate that amyloid-associated disruption of some step in neural processing can result in memory deficits.
Previously we have described decreased expression of genes critical for learning and memory and impaired induction of several immediate early genes (IEGs) in aged, memory deficient APP+PS1 mice [6, 7]. Increased neural activity during learning is argued to be a primary inducing stimulus for these IEGs . One possible mechanism to describe this phenomenon would be that amyloid is diminishing the ability of neurons to facilitate sufficient electrical signaling to induce changes in synaptic plasticity essential for memory consolidation. Here we present evidence that in addition to decreased expression of Na+/K+ ATPase mRNA as previously described [6, 7], the activity of this enzyme is significantly decreased in the APP+PS1 hippocampus but not in the amyloid-free cerebellum. Perhaps not surprisingly ouabain, an Na+/K+ ATPase inhibitor, has been shown to impair memory consolidation [9, 10]. We decided to investigate further the interactions of Aβ and Na+/K+ ATPase activity to understand better the potential role of this enzyme in AD and memory dysfunction.
We used the APP+PS1 transgenic mouse model to better understand how the deposition of amyloid contributes to the consistent memory loss seen in these animals [11–14]. Specifically, we have found that Na+/K+ ATPase, a protein critical for not only brain function, but survival, is adversely affected by the presence of amyloid and this interaction may be driving a major pathological event in the progression of amyloid-associated dementia.
These findings led us to postulate that the osmotic imbalance brought on by an absence or inhibition of Na+/K+ ATPase may contribute to the swelling associated with dystrophic neurites found in the vicinity of congophilic plaques in APP+PS1 mice and AD patients. We designed a dual immunostain utilizing immunohistochemical methods for Na+/K+ ATPase and immunofluorescence methods for phosphorylated neurofilament, a dystrophic neurite marker we evaluated earlier . Using this assay, we were able to demonstrate that the dystrophic neurites were almost exclusively present within the zone surrounding the congophilic plaque that lacked Na+/K+ ATPase staining. This is represented in a triple staining overlay of the fluorescent neurites from figure 4C onto the bright field image of Na+/K+ ATPase and Congo red staining from figure 4B (Figure 4D). The arrows in figure 4C demarcate where dystrophic neurites are present.
Over the past 6 years, our group has characterized various aspects of the APP+PS1 transgenic mice including their pathology, behavior, and gene expression. With age, these mice progressively develop more amyloid plaques surrounded by dystrophic neurites, activated microglia and astrocytes . With increasing amyloid burden, aged animals consistently develop memory deficits in the radial arm water maze (RAWM; [13, 18, 19], and, there is as yet no evidence for neuronal or synaptic loss. [6, 20, 21]. We have also demonstrated that several genes critical for synaptic plasticity and memory consolidation are down-regulated in these mice exclusively in those brain regions which accumulate amyloid  and the induction of a subset of immediate-early genes is impaired when the transgenic mice are introduced to a novel environment .
Here, we show that Na+/K+ ATPase has decreased enzyme activity in the amyloid-containing hippocampus of APP+PS1 transgenic mice. We have also demonstrated by immunohistology that Na+/K+ ATPase protein expression is reduced in the immediate vicinity of congophilic plaques, a zone where dystrophic neurites are most prevalent, suggesting that disrupted ionic homeostasis may contribute to their formation. Additionally, high concentrations of Aβ 1–42 directly inhibit the activity of Na+/K+ ATPase. This suggests that in the area surrounding amyloid plaques, where the local Aβ concentration is likely high, Na+/K+ ATPase activity may be locally inhibited.
From previous gene expression studies, we found that the mRNA for the Na+/K+ ATPase αIII subunit was consistently down-regulated ~30% in the hippocampi of APP+PS1 mice compared to non-transgenic littermates and to the amyloid-free cerebella . These reductions were also demonstrated in human Alzheimer's disease samples, consistent with data from previous investigations [6, 22]. Using a sensitive colorimetric assay to measure activity of Na+/K+ ATPase modified from Ellis et al. , we were able to demonstrate that in the APP+PS1 hippocampus, the specific activity of ouabain-sensitive ATPase was significantly reduced (figure 1B) while Na+/K+ ATPase activity in the amyloid-free cerebellum remained unperturbed with respect to genotype. Cerebellar activity was substantially lower than that seen in the non-transgenic hippocampal tissue, perhaps indicative of the abundant white matter found in this region, where Na+/K+ ATPase activity is low. These data demonstrate that the function of Na+/K+ ATPase is perturbed in a brain region that contains high overall concentrations of Aβ.
Previous investigations have shown that Na+/K+ ATPase protein levels are decreased in AD tissue but not in normal aged tissue [24, 25], but it is difficult to dissociate the loss due to neuronal death from any loss caused directly by Aβ inhibition. This demonstration that reduced activity along with a trend for reduced protein levels can be determined in homogenates from animal models of amyloid deposition argues that at least some of this loss in AD brain is associated with direct actions of Aβ. In vitro data suggests that Na+/K+ ATPase activity can be blocked directly by various Aβ peptide fragments in cultured neurons  and that even the purified enzyme can be inhibited by high concentrations of Aβ (Figure 5).
When we immunostained transgenic mouse tissue to visualize the distribution of Na+/K+ ATPase alpha III subunits we found that in areas where congophilic plaque staining was apparent, Na+/K+ ATPase staining was absent, and more specifically, there appeared to be no or little Na+/K+ ATPase staining in a penumbral zone surrounding the plaques stained with Congo red (Figures 3E–H and 4A–B). While most immunostaining protocols detect voids at the sites where congophilic plaques are located, these areas appeared somewhat larger in the Na+/K+ ATPase immunostained sections. This led us to speculate about that a reduction in the activity of this extremely important enzyme may have severe impacts on the functions of neurons in the vicinity of the deposits.
We knew from previous studies that dystrophic neurites could be visualized surrounding amyloid plaques in the APP+PS1 mice. And we have demonstrated previously that proteins such as synaptophysin and APP are in fact increased in dystrophic neurites . Therefore, we decided to stain sections for Na+/K+ ATPase and dystrophic neurites, along with amyloid plaques using Congo red, to determine whether Na+/K+ ATPase was absent from these neurites and in their immediate vicinity. We found empirically that staining the ATPase with a peroxidase label and the phosphorylated neurofilament with a fluorescein label to detect dystrophic neurites was the most effective way to see both markers on the same section along with the Congo red stained plaques. Imaging of these sections revealed that dystrophic neurites are in the circumferential area surrounding the congophilic amyloid plaques where Na+/K+ ATPase staining is absent (Figure 4D).
One possible explanation for this putative relationship would be that Aβ associated inhibition of Na+/K+ ATPase activity would result in osmotic imbalance and cause the neurites to begin swelling. In addition to the loss of electronic properties and accompanying dysregulation of neuronal signaling, these changes might even feedback to influence gene expression. Indeed, Huang et al. demonstrated that cells exposed to ouabain have reduced Na+/K+ ATPase αIII subunit mRNA expression . An alternative pathway may involve interactions of Aβ with surface proteins, such as integrins [28, 29]. and focal adhesion proteins  leading to activation of signal transduction cascades that mediate tyrosine phosphorylation . Bozulic et al. reported that the tyrosine kinase, Lyn, can phosphorylate Na+/K+ ATPase resulting in its removal from the membrane . These findings suggest that either direct inhibition of Na+/K+ ATPase by amyloid or its removal due to amyloid-mediated activation of a signaling cascade, could contribute to the formation of dystrophic neurites due to osmotic and/or ionic imbalances.
Aβ has been shown to bind various cell surface proteins [26, 33, 34]. and induce neuro-toxicity in vitro [35–37]. To determine the effect of Aβ 1–42 on Na+/K+ ATPase activity, we pre-incubated purified Na+/K+ ATPase with Aβ then colorimetrically measured enzyme activity. Although both preparations of Aβ did suppress activity at 112 μg/ml (~10 μM) and 225 μg/ml (~50 μM), it was the highest concentration (450 μg/ml or ~100 μM) of the soluble Aβ suspension that precipitated the largest reduction in activity compared to vehicle, nearly rendering it completely inactive (Figure 5). The fibrillar Aβ preparation did not exact the same precipitous decline in activity, demonstrating that it is not simply an artifact caused by high concentrations of a peptide that reduced activity. Further investigations will be required to determine which physicochemical form of Aβ is causing the reduced activity. This suggests that the Aβ can directly bind to the Na+/K+ ATPase and decrease its activity. Mark et al. suggests that the 25–35 amino acid region of the Aβ peptide induces oxidative stress thereby impairing Na+/K+ ATPase activity , and the findings presented herein are consistent with this earlier work.
These data indicate that Aβ deposition in transgenic mice is associated with reduced activity of Na+/K+ ATPase. In vitro studies suggest that high concentrations of Aβ can quickly inactivate the enzyme activity. One area in the brain that might harbor Aβ concentrations sufficient to suppress the activity of Na+/K+ ATPase would be the micro-domain near and immediately around the plaques. This is the area demonstrated to have reduced immunostaining for Na+/K+ ATPase, while exhibiting increased phosphorylated neurofilament staining consistent with dystrophic neurites. These results lead to the possibility that one factor contributing to the formation of dystrophic neurites is loss of ionic homeostasis. Such changes might explain the "swollen" nature of these neuronal processes in the vicinity of plaques. It might also lead to sufficient disruption of electro-chemical properties as to disrupt normal information processing and lead to memory dysfunction. If these suggestions are correct, drugs targeted at activating Na+/K+ ATPase and maintaining ionic balance in these neurons may benefit Alzheimer's patients by delaying the onset of neuritic dystrophia and memory dysfunction.
Mice were bred in our facility and genotyped using previously described methods  The working memory performance of the APP+PS1 mice used in these studies was impaired when compared to non-transgenic littermates as published previously ; untreated groups were studied here). For tissue collection, 17–18 month old mice were deeply anesthetized with pentobarbital (100 mg/kg) and perfused transcardially with phosphate buffered saline. Brains were removed and bisected into right and left hemispheres. The right hemisphere was immediately dissected into regions that were immediately frozen on dry ice, while the left hemisphere was post-fixed in 4% para-formaldehyde for 24 hours and subsequently processed through a cryo-protection schedule of 10, 20 and 30% sucrose. Frozen brains were sectioned horizontally on a sliding microtome at 25 μm and stored in Dulbecco's phosphate buffered saline plus azide at 4°C.
Na+/K+ ATPase activity assay and amyloid preparation
An assay to detect specific activity of Na+/K+ ATPase by measuring the release of phosphate was developed using a variation of the method described by Ellis et al. . Freshly frozen dissected hippocampi, cortex and cerebella (20–30 mg tissue weight) from APP+PS1 and non-transgenic littermates were homogenized using a rotor-stator homogenizer in 1 ml of cold suspension buffer containing 85 mM sodium chloride (NaCl), 20 mM potassium chloride (KCl), 4 mM magnesium chloride (MgCl), 0.2 mM EGTA and 30 mM histidine pH 7.2. Saponin was added to the samples to a final concentration of 20 μg/ml. They were then incubated at 37°C for 15 minutes. Protein concentration was measured by Bradford assay and concentrations were adjusted to 10 mg/ml.
In a 96-well plate, 60 μl of ATP buffer containing 140 mM NaCl, 20 mM KCl, 3 mM MgCl, 30 mM histidine and 3 mM ATP were added to wells. Two sets of samples were included, one with ATP buffer only and the other with 100 μM of the Na+/K+ ATPase selective inhibitor ouabain added to the ATP buffer. Subsequently, 10 μl of protein homogenates were added to the ATP buffer ± ouabain, which were then mixed by pipetting and incubated at 37°C for 30 minutes. The reaction was stopped by adding 120 μl of an acid molybdate solution consisting of 0.5 g ammonium molybdate (Sigma, St. Louis, MO) in 0.5 M sulfuric acid. After mixing, 10 μl of Fiske Subbarow Reducer (Sigma, St. Louis, MO) was added and wells were mixed again. The plate was allowed to incubate covered at room temperature for 10 minutes and then measured spectrophotometrically at 660 nm. A standard curve of phosphoric acid dilutions was used to calculate the specific activity of the ouabain sensitive ATP hydrolysis and converted to μmols of inorganic phosphate (Pi) liberated/mg protein/ hour. All reactions were performed in triplicate, which were then averaged to produce the single value for the sample. Differences between APP+PS1 and non-transgenic mice were analyzed for significance using one-way ANOVA. Aβ used for these studies was generated by resuspending 1 mg of commercially available recombinant Aβ 1–42 peptide (rPeptide, Athens, GA) in 221 μl of 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP, Sigma, St. Louis, MO) to generate 45 μg Aβ 1–42 films. These films were resuspended in 2 μl of anhydrous DMSO, followed by agitation and subsequent addition of either 48 μl of cold water followed by overnight incubation at 4°C (for soluble Aβ preparation) or 10 mM HCl followed by overnight incubation at 37°C (for fibrillar Aβ preparation). The acid was neutralized the following day by the addition of NaOH. These preparations yielded approximately 900 μg/ml suspensions of Aβ.
For analysis of activity inhibition by both preparations of Aβ, purified Na+/K+ ATPase (from brain; Sigma, St. Louis, MO) was pre-incubated for 2 hours in a 37°C orbital shaker separately with 112.5, 225 and 450 μg/ml of either a DMSO+water Aβ suspension or a DMSO+neutralized HCl Aβ suspension. Vehicle alone was also used for each preparation and sample values are indicated as a percentage of the "vehicle only" values. Activity was then measured using the same activity assay as above and significance was measured using one-way ANOVA comparing activity between vehicle treated and Aβ treated.
Brain homogenate from cortical tissue was equilibrated to 10 μg of total protein. This homogenate, along with 1 μg of purified cerebral Na+/K+ ATPase, was diluted 1:1 with loading buffer containing 4% SDS and 5% β-mercaptoethanol, heated to 95°C for 5 minutes and loaded onto a 7.5% Tris-glycine gel which was electrophoresed at 100 mV for one hour in the presence of SDS. The protein was subsequently transferred onto an Immobilon membrane (Millipore, Billerica, MA) for one hour at 100 mV. The blot was rinsed with borate saline + 0.05% Tween-20 (BST) and blocked overnight at 4°C in 5% non-fat dry milk (NFDM). The following day, a 1:2000 dilution of rabbit anti-rat Na+/K+ ATPase αIII antibody (Upstate Biotech, Lake Placid, NY) in 0.5% NFDM+BST was applied to the blot for 1 hour, followed by washing and a subsequent 1 hour incubation with a 1:5000 dilution of hrp-labeled anti-rabbit IgG (Sigma, St. Louis, MO) in 0.5% NFDM+BST. After washing, the blot was developed for chemiluminescence using a luminol substrate kit (Santa Cruz Biotech, Santa Cruz, CA). Band density was quantified using the SoftMax Pro program and one-way ANOVA was used to determine significance.
Immunohistochemical and immunofluorescence analyses for Na+/K+ ATPase αIII and phosphorylated neurofilament, respectively, were performed on the same 25 μm free-floating hippocampal sections. Sections were treated 15 minutes with 10% methanol, 3% hydrogen peroxide and 80% phosphate buffered saline (PBS) to block endogenous peroxidase activity, and then washed 3 times with PBS. Sections were subsequently treated with sodium borohydride for 15 minutes to reduce background auto-fluorescence  followed by washing with PBS. Sections were then permeabilized for 30 minutes with 100 mM lysine, 0.2% triton x-100, 2% goat serum and 2% horse serum in PBS, and washed 3 times with PBS. Because one antibody was murine being used on mouse tissue, endogenous mouse IgG was first blocked with a 1:300 dilution of goat F (ab') 2 anti-mouse IgG (overnight; Protos Immunoresearch, Burlingame, CA). Sections were washed the following day and co-incubated with a 1:5000 dilution of a rabbit anti-rat Na+/K+ ATPase αIII IgG (Upstate Biotech, Lake Placid, NY) and a 1:10,000 dilution of a mouse monoclonal IgG1 ascites pool specific for phosphorylated forms of neurofilament (SMI-312; Sternberger Monoclonals, Lutherville, MD) in 2% goat serum and 2% horse serum in PBS. The following day, sections were washed, and then co-incubated in both a 1:3000 dilution of anti-rabbit biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) and a 1:100 dilution of anti-mouse fluorescein conjugated secondary antibody (Vector Labs, Burlingame, CA) for 2 hours. After washing, the tissue was incubated with Vectastain® Elite® ABC kit (Vector Labs, Burlingame, CA). The tissue was then washed and stained with a diaminobenzidine: peroxide system plus nickel enhancement (DAB/Ni2+), followed by final washes. Compact amyloid plaques were visualized using Congo red staining after sections were slide mounted and dried . Briefly, slides were incubated in alkaline alcoholic saturated sodium chloride (AASSC), followed by 0.2% Congo red in AASSC, then dehydrated and cover-slipped with xylene-free Vectamount (Vector Labs, Burlingame, CA). Other mounting media were tested, but only Vectamount was suitable for combined immunohistochemistry, immunofluorescence and Congo red staining. The extent of nonspecific binding was assessed in the absence of primary antibodies for all assays. Specificity of the Na+/K+ ATPase antibody was confirmed by reduced staining following a 2 hour pre-incubation of the antibody with purified cerebral Na+/K+ ATPase at a 1 antibody to 4 enzyme molecule ratio. Both immunostains were characterized individually before the co-incubation procedure was implemented.
This work was supported by AG15490 and AG18478 from NIH.
- Selkoe DJ: Clearing the brain's amyloid cobwebs. Neuron. 2001, 32: 177-180. 10.1016/S0896-6273(01)00475-5.View ArticlePubMedGoogle Scholar
- Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996, 274: 99-102. 10.1126/science.274.5284.99.View ArticlePubMedGoogle Scholar
- Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S: Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996, 383: 710-713. 10.1038/383710a0.View ArticlePubMedGoogle Scholar
- Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998, 4: 97-100. 10.1038/nm0198-097.View ArticlePubMedGoogle Scholar
- Morgan D: Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochem Res. 2003, 28: 1029-1034. 10.1023/A:1023255106106.View ArticlePubMedGoogle Scholar
- Dickey CA, Loring JF, Eastman PS, Montgomery JR, Gordon M, Morgan DG: Selectively reduced expression of synaptic plasticity-related genes in APP+PS1 transgenic mice. J Neurosci. 2003, 23: 5219-5226.PubMedGoogle Scholar
- Dickey CA, Gordon MN, Mason JE, Wilson NJ, Diamond DM, Guzowski JF, Morgan D: Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. J Neurochem. 2004, 88: 434-442.View ArticlePubMedGoogle Scholar
- Dragunow M: A role for immediate-early transcription factors in learning and memory. Behav Genet. 1996, 26: 293-299.View ArticlePubMedGoogle Scholar
- Watts ME, Mark RF: Separate actions of ouabain and cycloheximide on memory. Brain Res. 1971, 25: 420-423. 10.1016/0006-8993(71)90450-1.View ArticlePubMedGoogle Scholar
- Mark RF, Watts ME: Drug inhibition of memory formation in chickens. I. Long-term memory. Proc R Soc Lond B Biol Sci. 1971, 178: 439-454.View ArticlePubMedGoogle Scholar
- Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000, 408: 982-985. 10.1038/35050116.View ArticlePubMedGoogle Scholar
- Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D: Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol. 2002, 173: 183-195. 10.1006/exnr.2001.7754.View ArticlePubMedGoogle Scholar
- Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, Diamond DM: Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 2001, 891: 42-53. 10.1016/S0006-8993(00)03186-3.View ArticlePubMedGoogle Scholar
- Austin LA, Arendash GW, Gordon G, Diamond DM, DiCarlo G, Dickey C, Ugen KE, Morgan D: Short-term A-beta vaccinations do not improve cognitive performance in cognitively-impaired APP+PS1 mice. Behav Neurosci. 2003Google Scholar
- Stefanovic V, Ebel A, Hermetet JC, Mandel P: Na+-K+-ATPase activity in brain regions of C57 and DBA mice. J Neurochem. 1974, 22: 1139-1141.View ArticlePubMedGoogle Scholar
- Brines ML, Gulanski BI, Gilmore-Hebert M, Greene AL, Benz EJJ, Robbins RJ: Cytoarchitectural relationships between [3H]ouabain binding and mRNA for isoforms of the sodium pump catalytic subunit in rat brain. Brain Res Mol Brain Res. 1991, 10: 139-150. 10.1016/0169-328X(91)90104-6.View ArticlePubMedGoogle Scholar
- Maki AA, Baskin DG, Stahl WL: [3H]-ouabain binding sites in rat brain: distribution and properties assessed by quantitative autoradiography. J Histochem Cytochem. 1992, 40: 771-779.View ArticlePubMedGoogle Scholar
- Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D: Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet. 1999, 29: 177-185. 10.1023/A:1021691918517.View ArticlePubMedGoogle Scholar
- Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, Hatcher JM, DiCarlo G, Gottschall WP, Morgan D, Arendash GW: Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging. 2001, 22: 377-385. 10.1016/S0197-4580(00)00249-9.View ArticlePubMedGoogle Scholar
- Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, Hyman BT: Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol. 1998, 57: 334-337.View ArticlePubMedGoogle Scholar
- Takeuchi A, Irizarry MC, Duff K, Saido TC, Hsiao Ashe K, Hasegawa M, Mann DM, Hyman BT, Iwatsubo T: Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol. 2000, 157: 331-339.PubMed CentralView ArticlePubMedGoogle Scholar
- Chauhan NB, Lee JM, Siegel GJ: Na,K-ATPase mRNA levels and plaque load in Alzheimer's disease. J Mol Neurosci. 1997, 9: 151-166.View ArticlePubMedGoogle Scholar
- Ellis DZ, Nathanson JA, Sweadner KJ: Carbachol inhibits Na(+)-K(+)-ATPase activity in choroid plexus via stimulation of the NO/cGMP pathway. Am J Physiol Cell Physiol. 2000, 279: C1685-C1693.PubMedGoogle Scholar
- Harik SI, Mitchell MJ, Kalaria RN: Ouabain binding in the human brain. Effects of Alzheimer's disease and aging. Arch Neurol. 1989, 46: 951-954.View ArticlePubMedGoogle Scholar
- Liguri G, Taddei N, Nassi P, Latorraca S, Nediani C, Sorbi S: Changes in Na+,K(+)-ATPase, Ca2(+)-ATPase and some soluble enzymes related to energy metabolism in brains of patients with Alzheimer's disease. Neurosci Lett. 1990, 112: 338-342. 10.1016/0304-3940(90)90227-Z.View ArticlePubMedGoogle Scholar
- Mark RJ, Hensley K, Butterfield DA, Mattson MP: Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J Neurosci. 1995, 15: 6239-6249.PubMedGoogle Scholar
- Huang L, Kometiani P, Xie Z: Differential regulation of Na/K-ATPase alpha-subunit isoform gene expressions in cardiac myocytes by ouabain and other hypertrophic stimuli. J Mol Cell Cardiol. 1997, 29: 3157-3167. 10.1006/jmcc.1997.0546.View ArticlePubMedGoogle Scholar
- Sabo S, Lambert MP, Kessey K, Wade W, Krafft G, Klein WL: Interaction of beta-amyloid peptides with integrins in a human nerve cell line. Neurosci Lett. 1995, 184: 25-28. 10.1016/0304-3940(94)11159-G.View ArticlePubMedGoogle Scholar
- Goodwin JL, Kehrli MEJ, Uemura E: Integrin Mac-1 and beta-amyloid in microglial release of nitric oxide. Brain Res. 1997, 768: 279-286. 10.1016/S0006-8993(97)00653-7.View ArticlePubMedGoogle Scholar
- Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S, Bird IN, Varndell IM, Sheppard PW, Everall I, Anderton BH: Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. J Neurosci. 2002, 22: 10-20.PubMedGoogle Scholar
- Grace EA, Busciglio J: Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. J Neurosci. 2003, 23: 493-502.PubMedGoogle Scholar
- Bozulic LD, Dean WL, Delamere NA: The influence of Lyn kinase on Na,K-ATPase in porcine lens epithelium. Am J Physiol Cell Physiol. 2004, 286: C90-C96. 10.1152/ajpcell.00174.2003.View ArticlePubMedGoogle Scholar
- Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD: Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci. 2001, 21: 4125-4133.PubMedGoogle Scholar
- Verdier Y, Penke B: Binding Sites of Amyloid beta-Peptide in Cell Plasma Membrane and Implications for Alzheimer's Disease. Curr Protein Pept Sci. 2004, 5: 19-31.View ArticlePubMedGoogle Scholar
- Caughey B, Lansbury PT: Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003, 26: 267-298. 10.1146/annurev.neuro.26.010302.081142.View ArticlePubMedGoogle Scholar
- Stine WBJ, Dahlgren KN, Krafft GA, LaDu MJ: In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003, 278: 11612-11622. 10.1074/jbc.M210207200.View ArticlePubMedGoogle Scholar
- Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL: Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA. 2003, 100: 10417-10422. 10.1073/pnas.1834302100.PubMed CentralView ArticlePubMedGoogle Scholar
- Clancy B, Cauller LJ: Reduction of background autofluorescence in brain sections following immersion in sodium borohydride. J Neurosci Methods. 1998, 83: 97-102. 10.1016/S0165-0270(98)00066-1.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.